IPCALAB.NS Profit & Loss
Ipca Laboratories Ltd.
Profit & Loss Balance Sheet Cash Flow
Profit & Loss · 4 years on file
(FY2022-23 to FY2025-26)
· fetched 2026-08-23 23:31
| Line item | FY2022-23 | FY2023-24 | FY2024-25 | FY2025-26 | Source (XBRL element) |
|---|---|---|---|---|---|
| Revenue from Operations | ₹6,244.32 Cr. | ₹7,705.04 Cr. | ₹8,939.59 Cr. | ₹9,646.33 Cr. | RevenueFromOperations |
| Gross Revenue (incl. inter-segment) | N/A | N/A | N/A | N/A | SegmentRevenueFromOperations |
| Other Income | ₹125.62 Cr. | ₹124.77 Cr. | ₹92.80 Cr. | ₹174.45 Cr. | OtherIncome |
| Total Income | ₹6,369.94 Cr. | ₹7,829.81 Cr. | ₹9,032.39 Cr. | ₹9,820.78 Cr. | Income |
| Cost of Materials Consumed | ₹1,708.65 Cr. | ₹2,216.32 Cr. | ₹2,276.82 Cr. | ₹2,344.01 Cr. | CostOfMaterialsConsumed |
| Purchases of Stock-in-Trade | ₹497.19 Cr. | ₹490.07 Cr. | ₹547.78 Cr. | ₹532.62 Cr. | PurchasesOfStockInTrade |
| Changes in Inventories | ₹100.67 Cr. | ₹-130.64 Cr. | ₹-46.05 Cr. | ₹-53.91 Cr. | ChangesInInventoriesOfFinishedGoodsWorkInProgressAndStockInTrade |
| Employee Benefit Expense | ₹1,287.64 Cr. | ₹1,708.43 Cr. | ₹1,983.99 Cr. | ₹2,160.20 Cr. | EmployeeBenefitExpense |
| Finance Costs | ₹45.54 Cr. | ₹138.27 Cr. | ₹84.93 Cr. | ₹75.94 Cr. | FinanceCosts |
| Depreciation and Amortisation | ₹261.56 Cr. | ₹357.24 Cr. | ₹397.82 Cr. | ₹418.12 Cr. | DepreciationDepletionAndAmortisationExpense |
| Other Expenses | ₹1,723.40 Cr. | ₹2,099.70 Cr. | ₹2,450.91 Cr. | ₹2,684.85 Cr. | OtherExpenses |
| Total Expenses | ₹5,624.65 Cr. | ₹6,879.39 Cr. | ₹7,696.20 Cr. | ₹8,161.83 Cr. | Expenses |
| Profit Before Exceptional Items and Tax | ₹745.29 Cr. | ₹950.42 Cr. | ₹1,336.19 Cr. | ₹1,658.95 Cr. | ProfitBeforeExceptionalItemsAndTax |
| Exceptional Items | ₹0.00 Cr. | ₹-107.75 Cr. | ₹-205.05 Cr. | ₹-86.43 Cr. | ExceptionalItemsBeforeTax |
| Profit Before Tax | ₹745.29 Cr. | ₹842.67 Cr. | ₹1,131.14 Cr. | ₹1,572.52 Cr. | ProfitBeforeTax |
| Tax Expense | ₹253.36 Cr. | ₹313.46 Cr. | ₹343.61 Cr. | ₹381.15 Cr. | TaxExpense |
| Net Profit (incl. minority interest) | ₹478.99 Cr. | ₹522.92 Cr. | ₹785.24 Cr. | ₹1,183.78 Cr. | ProfitLossForPeriod |
| Net Profit (to shareholders) | ₹471.32 Cr. | ₹547.35 Cr. | ₹737.68 Cr. | ₹1,141.12 Cr. | ProfitOrLossAttributableToOwnersOfParent |
| Basic EPS | ₹18.58 | ₹21.57 | ₹29.08 | ₹44.98 | BasicEarningsLossPerShareFromContinuingAndDiscontinuedOperations |
| Diluted EPS | ₹18.58 | ₹21.57 | ₹29.08 | ₹44.98 | DilutedEarningsLossPerShareFromContinuingAndDiscontinuedOperations |
Every figure above is the exact value of the named XBRL element from IPCALAB.NS's cached filing for that year — nothing here is estimated or backfilled. A company shows one column per year StockProof actually has data for — never padded with blank years. Rows shown as N/A are genuinely not disclosed under that year's filing format (see peer comparison for how other Healthcare companies compare).